Recombinant human adenovirus type 5-vectored vaccine expressing avian reovirus σC protein protects against prevalent genotype I avian reovirus in chickens Authors: Xiyao Cui, Zhenrui Song, Defang Zhou, Liangyu Yang, Hongbo Chen, Hui Zhang, Ziqiang Cheng Published: 2026 ABSTRACT AbstractAvian reovirus (ARV) is a globally important poultry pathogen causing substantial economic losses due to viral arthritis, enteritis and immunosuppression. Traditional vaccines based on the S1133 strain are less effective against circulating ARV variants due to genetic divergence. The σC protein is the primary antigen inducing neutralizing antibodies against ARV, making it a key target for vaccine development. Here, we constructed a recombinant human adenovirus type 5 (rHAdV5) vector vaccine expressing the σC protein of a prevalent Chinese ARV field strain (SDAU-1) and evaluated its safety, immunogenicity and protective efficacy in specific-pathogen-free (SPF) chickens. The recombinant vaccine rHAdV5-ARV-σC stably expressed the ∼36 kDa σC protein and maintained genetic stability over 13 serial passages. Immunization of 1-day-old SPF chickens with 10⁹ PFU rHAdV5-ARV-σC elicited robust ARV-specific IgG antibodies (peak titer 1:3500 at 7 days post-immunization) and significantly elevated serum IFN-γ and IL-4 levels (P < 0.05), indicating activation of both humoral and cellular immune responses. Following challenge with the SDAU-1 strain at 7 days of age, the vaccine provided an 86% (26/30) protection rate, markedly reduced viral shedding and tissue viral loads, and alleviated pathological lesions and immune organ damage compared to unvaccinated controls. These results demonstrate that rHAdV5-ARV-σC is a safe, immunogenic, and effective vaccine candidate against prevalent ARV strains, with high potential for controlling ARV infections in commercial poultry production.Keywords: Avian reovirus, σC protein, Recombinant adenovirus vector, Vaccine, Immunogenicity Introduction Avian reovirus (ARV) is a significant pathogen in the poultry industry, primarily causing viral arthritis and tenosynovitis, which lead to substantial economic losses due to increased morbidity, mortality, and condemnations (Nour and Mohanty, 2024). The virus’s segmented double-stranded RNA genome facilitates rapid evolution, resulting in considerable genetic and antigenic diversity among circulating strains (Egana-Labrin and Broadbent, 2023). The outer capsid protein sigma C (σC), encoded by the S1 genome segment, is the primary viral attachment protein and a major target for type-specific neutralizing antibodies, making it a key determinant in protective immunity (Goldenberg et al., 2016; Nour and Mohanty, 2024). Consequently, sequence analysis of the σC gene has become the standard for genotyping, and ARV isolates are currently classified into at least seven distinct genotypic clusters (Sellers, 2022). Vaccination of breeder flocks with live-attenuated and inactivated vaccines is the principal strategy to control ARV by providing maternal-derived antibodies to progeny. Historically, commercial vaccines based on genotype I strains like S1133 were effective. However, in the past decade, outbreaks of viral arthritis in vaccinated broiler flocks have surged worldwide, with studies reporting the co-circulation of multiple genetic clusters, including genotypes II through VI, on commercial farms (Lu, et al., 2015; Shabbir, et al., 2024). Molecular epidemiological investigations consistently reveal that currently circulating ARV field variants are genetically distant from commercial vaccine strains, with amino acid sequence identities of the σC protein often below 80% (Liu, et al., 2023; Mosad, et al., 2023). This antigenic mismatch is the primary cause of vaccine failure, as classical vaccines fail to induce cross-protective neutralizing antibodies against emerging variant strains (Liu, et al., 2023; Lublin, et al., 2011). Even within genotype I, novel variants have emerged that exhibit substantial antigenic divergence from the S1133 vaccine strain, allowing them to evade vaccine-induced immunity and cause severe disease in immunized chickens (Liu, et al., 2023). This situation necessitates the development of new vaccine platforms that can be rapidly updated to match field variants. Subunit vaccines based on the σC protein have shown promise in eliciting protective immune responses (Goldenberg, et al., 2016; Wu, et al., 2005). It was demonstrated that an optimized fragment of the σC protein (residues 122-326) expressed in Escherichia coli could induce neutralizing antibodies comparable to a whole-virus vaccine. More recently, Li et al. confirmed the strong immunogenicity and protective efficacy of recombinantly expressed σC protein from a prevalent ARV isolate (Li et al., 2026). Recombinant viral vectors, such as human adenovirus type 5 (HAdV5), offer an alternative platform with advantages in antigen delivery, induction of both humoral and cellular immunity, and potential for mass application. Adenovirus-vectored vaccines have been successfully developed for other avian diseases and have shown great potential in the poultry industry. Although previous research on using lactic acid bacteria as a vector for delivering the ARV σC protein showed enhanced mucosal immune responses (Lin, et al., 2012), the efficacy of a replication-defective HAdV5-vectored vaccine expressing the σC protein has not been evaluated in chickens. The objective of this study was to construct a recombinant HAdV5 (rHAdV5) expressing the σC protein of a prevalent genotype 1 ARV field strain (SDAU-1) and to assess its immunogenicity and protective efficacy in specific-pathogen-free chickens, thereby providing a novel strategy for ARV control. Materials and methods Ethical statement All animal experiments were approved by the Animal Care and Use Committee of Shandong Agricultural University (Approval No.: SDAU-AEC-2023-0012) and conducted in strict accordance with the Guidelines for the Care and Use of Laboratory Animals in China. Viruses, cells, and animals The ARV field strain SDAU-1 was isolated previously and deposited in GenBank (Accession No: OR520153). Chicken hepatocellular carcinoma (LMH) cells and human embryonic kidney (293T) cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM; Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS; Thermo Fisher Scientific, Waltham, MA, USA) and 1% penicillin-streptomycin (Sigma-Aldrich, St. Louis, MO, USA) at 37°C in a 5% CO₂ incubator. One-day-old SPF chicks and 7-day-old SPF embryonated chicken eggs were purchased from Jinan SPAFAS Poultry Co., Ltd. (Jinan, China). Construction of recombinant adenovirus rHAdV5-ARV-σC The full-length σC gene (981 bp) was amplified from SDAU-1 cDNA using specific primers (Forward: 5′-TGGACGGATTAACTCAACAGCAGCGAA-3′; Reverse: 5′-TTAGGTATCGATGCCCGTACGCACGGT-3′). The purified target gene fragment was then cloned into the pShuttle-CMV shuttle vector (Clontech, Mountain View, CA, USA), which had been linearized using EcoRI and BamHI restriction enzyme sites, via seamless cloning technology to generate the recombinant shuttle plasmid pShuttle-CMV-σC. The recombinant shuttle plasmid was linearized with PmeI and co-transfected with the Admax adenoviral backbone vector (pHAdV5) (Obio Technology, Shanghai, China) into 293T cells using Lipofectamine 3000 (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s protocol. HAdV5-ARV-σC was rescued by homologous recombination in 293T cells. Plaques expressing green fluorescent protein (GFP) were picked and purified 3 times to ensure viral purity. The virus was amplified in 293T cells, concentrated by ultracentrifugation (25,000×g for 2 h at 4°C), and purified by cesium chloride density gradient centrifugation. Characterization of rHAdV5-ARV-σC Virus titer was measured using an adenovirus titer detection kit (immunostaining assay; Beyotime Biotech, Shanghai, China) on 293T cells. Briefly, serial 10-fold dilutions of the purified virus were inoculated onto confluent 293T cells in 96-well plates. After 48 h of incubation at 37°C with 5% CO₂, cells were fixed with 4% paraformaldehyde, stained with anti-adenovirus hexon antibody, and visualized with HRP-conjugated secondary antibody. The virus titer was expressed as plaque-forming units per mL (PFU/mL). 293T cells were infected with rHAdV5-ARV-σC at a multiplicity of infection (MOI) of 10. At 48 h post-infection, cells were lysed with RIPA buffer (Beyotime Biotech, Shanghai, China) containing protease inhibitors. Protein expression was detected by Western blot: proteins were separated by 12% SDS-PAGE, transferred to PVDF membranes, blocked with 5% non-fat milk for 1 h at room temperature, and incubated with rabbit anti-σC polyclonal antibody (1:1000) at 4°C overnight, followed by HRP-conjugated goat anti-rabbit IgG (1:5000; Beyotime Biotech, Shanghai, China) for 1 h at room temperature. Bands were visualized using an ECL chemiluminescence kit (Thermo Fisher Scientific, Waltham, MA, USA). rHAdV5-ARV-σC was serially passaged 13 times in 293T cells. At passages 1, 5, 9, and 13, viral genomic DNA was extracted to serve as a template. The integrity of the inserted σC gene was verified by PCR using specific primers designed based on conserved ARV σC sequences. The PCR cycling conditions were as follows: initial denaturation at 95°C for 3 min; 35 cycles of 95°C for 15 s, 60°C for 15 s, and 72°C for 30 s; and a final extension at 72°C for 5 min. The resulting 981 bp PCR products were analyzed by agarose gel electrophoresis. Furthermore, σC protein expression was confirmed by Western blot as described above. Immunogenicity and dose determination To evaluate the immunogenicity and determine the optimal immunization dose, a total of 120 one-day-old SPF chicks were randomly divided into 4 groups (n = 30/group): three vaccination groups (rHAdV5-ARV-σC-10⁷, rHAdV5-ARV-σC-10⁸, and rHAdV5-ARV-σC-10⁹) and a Mock group. At 1 day of age, chicks in the three vaccination groups were immunized via intramuscular injection (IM) with 100 μL of the recombinant vaccine containing 10⁷, 10⁸, or 10⁹ PFU, respectively. Simultaneously (at 1 day of age), chicks in the Mock group were injected with 100 μL of sterile PBS via IM. Body weight was recorded weekly. Serum samples were collected at 4, 7, 14, 21, 28 and 35 dpi. ARV-specific IgG antibody levels were measured by an indirect ELISA. Briefly, 96-well microtiter plates were coated with 100 μL/well of purified σC protein (1 μg/mL) at 4°C overnight. After washing three times with washing buffer, the plates were blocked with 200 μL of 5% skim milk per well for 1.5 h at 37°C. Subsequently, 100 μL of serially diluted chicken serum samples were added to each well and incubated for 1 h at 37°C. After another three washes, 100 μL of HRP-conjugated goat anti-chicken IgG secondary antibody (1:5000 dilution) was added to each well and incubated for 1 h at 37°C. The reaction was developed using a chromogenic substrate for 15 min at 37°C and then stopped with a stop solution. The optical density (OD) was measured at 450 nm using a microplate reader. Serum IFN-γ and IL-4 levels were quantified using commercial chicken ELISA kits (R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s instructions. Protective efficacy A total of 120 one-day-old SPF chicks were randomly divided into 4 groups (n = 30/group): rHAdV5-ARV-σC + ARV-SDAU-1 group: Immunized with 10⁹ PFU/mL rHAdV5-ARV-σC (100 μL, IM) at 1 day old; challenged with 100 ELD₅₀ ARV-SDAU-1 (oral) at 7 days old. rHAdV5-ARV-σC group: Immunized with rAd5-ARV-σC as described above; no challenge. ARV-SDAU-1 group: PBS injection (100 μL, IM) at 1 day old; challenged with SDAU-1 as described above. Mock: PBS injection (100 μL, IM) and no challenge. Chicks were observed daily for clinical signs (lethargy, lameness, diarrhea). Body weight was recorded at 7, 14, 21, 28 and 35 days of age. The protection rate was defined as the percentage of chicks in the rHAdV5-ARV-σC + ARV-SDAU-1 group with body weight ≥94% of the Mock group average at 35 days of age. Serum samples were collected at 7, 14, 21 and 28 days post-challenge (dpc) to measure σC-specific IgG antibody levels by indirect ELISA as described above. Cloacal swabs were collected from each chick at 3, 7, 11 and 15 dpc. Swabs were suspended in PBS (1:10, w/v), and viral RNA was extracted for qPCR targeting the σC gene (Forward: 5′-GCTGCTGCTGCTGCTGCT-3′; Reverse: 5′-GGTGGTGGTGGTGGTGGT-3′; Probe: 5′-FAM-TGCTGCTGCTGCTGCTGCTGCT-TAMRA-3′). At 3, 7, 14 and 21 dpc, 5 chicks per group were euthanized. The liver, spleen, bursa of Fabricius, thymus, and duodenum were collected, homogenized in PBS (1:10, w/v), and viral RNA was detected by qPCR. Viral load was expressed as log₁₀ copies/μg RNA. Spleen, bursa of Fabricius, and thymus were weighed at 7, 14, and 21 dpc. The organ index was calculated as (organ weight [g] / body weight [kg]). At 28 dpc, 5 chicks per group were euthanized for gross lesion observation. Tissues (tendon, bursa of Fabricius, thymus, duodenum) were fixed in 10% neutral buffered formalin, embedded in paraffin, sectioned (4 μm), stained with hematoxylin and eosin (H&E), and observed under a light microscope. Statistical analysis Data were analyzed using SPSS 13.0 software (IBM, Armonk, NY, USA) and presented as mean ± standard deviation (SD). Prior to ANOVA, the assumptions for parametric testing were evaluated. Data normality was confirmed using the Shapiro-Wilk test, and homogeneity of variances was verified using Levene’s test. Differences between groups were tested by one-way ANOVA followed by Tukey’s multiple comparison test. P < 0.05 was considered statistically significant, P < 0.01 very significant, and P < 0.001 extremely significant. Graphs were generated using GraphPad Prism 9.0 (GraphPad Software, San Diego, CA, USA). Results Construction and characterization of rHAdV5-ARV-σC The recombinant virus rHAdV5-ARV-σC was designed as shown in Fig. 1A and successfully rescued, as confirmed by GFP expression in 293T cells (Fig. 1B). Western blot analysis detected a specific ∼36 kDa protein corresponding to the σC protein . The purified virus had a titer of 7.11×10¹⁰ PFU/mL (Fig. 1C). PCR and Western blot confirmed the integrity of the σC gene and protein stable expression at passages 1, 5, 9 and 13 (Fig. 1D), indicating good genetic stability. Construction and functional validation of the rHAdV5-ARV-σC. Construction of the recombinant shuttle plasmid, pcADV-EF1-GFP-ARV-σC—HA. The shuttle plasmid was co-transfected with the AdMax™ backbone plasmid into HEK293 cells. Successful viral packaging was confirmed by the expression of GFP, observed on 2 days post-transfection. G: Green fluorescence image of transfected HEK293 cells. Mock: Control cells transfected with an empty vector. Titration of rHAdV5-ARV-σC. Cells in wells were infected with serial dilutions of the virus, and the 10⁻8 dilution yielded an optimal number of positive cells (3–5 brown signals per field of view) for quantification. The viral titer was determined to be 7.11×10¹⁰ PFU/mL. (D) Genetic stability, gene and protein expression of σC from rHAdV5-ARV-σC were confirmed. P1, P5, P9 and P13 mean the serial passages for 1, 5, 9 and 13 of rHAdV5-ARV-σC in 293T cells. Pos=positive control; Neg=negative control. Immunogenicity of rAd5-ARV-σC One-day-old chicks were immunized intramuscularly with 100 µL of the vaccine at three doses (10⁷, 10⁸, or 10⁹ PFU). Blood samples were collected at 4, 7, 14, 21, 28 and 35 dpi (Fig. 2A). All vaccinated chicks remained healthy with no adverse effects on body weight compared to the Mock group (P > 0.05) (Fig. 2B). The 10⁹ PFU/mL dose induced the highest σC-specific IgG antibody levels, peaking at 1:3500 at 7 dpi and maintaining 1:1500 until 35 dpi (Fig. 2C). Lower doses (10⁸ and 10⁷ PFU/mL) induced peak antibodies of 1:2200 and 1:1800, respectively, which declined more rapidly. Serum IFN-γ and IL-4 levels in the 10⁹ PFU/mL group were significantly higher than those in the Mock group from 4 to 21 dpi (P < 0.05) (Fig. 2D and E), indicating activation of both Th1 and Th2 immune pathways. Based on these results, the 10⁹ PFU/mL dose was selected for the protective efficacy study. Assessment of the immunogenicity of the rHAdV5-ARV-σC. Schematic of the immunization and sampling schedule. One-day-old chicks were immunized intramuscularly with 100 µL of the vaccine at three doses (10⁷, 10⁸, or 10⁹ PFU). Blood samples were collected at 4, 7, 14, 21, 28 and 35 dpi. Body weight changes in SPF chicks following vaccination. Levels of σC specific antibodies after immunization with different vaccine doses. (D, E) Serum levels of the cytokines IFN-γ (D) and IL-4 (E) in chicks at 4, 7, 14 and 21dpi. One-way ANOVA was performed using GraphPad Prism 8. All data are presented as the mean±standard deviation (SD). Statistical significance is indicated as follows: ns, not significant, p > 0.05; *p < 0.05; **p < 0.01. Protective efficacy against ARV challenge One-day-old chicks were immunized intramuscularly with a 100 µL dose of the vaccine of rHAdV5-ARV-σC (109 PFU). At 7 days old, the chicks were challenged with 100 ELD₅₀ SDAU-1 (oral). The chicks were monitored for clinical signs and body weight until 28 dpc (Fig. 3A). Tissue samples for immune organ index (IOI) analysis were collected at 7, 14, and 21 dpc (Fig. 3C). The chickens in the ARV-SDAU-1 group exhibited clinical signs (lethargy, lameness, diarrhea) from 5 dpc, with significantly reduced weight gain compared to the other groups (P < 0.01) (Fig. 3B). The chickens in rHAdV5-ARV-σC+ARV-SDAU-1 and rHAdV5-ARV-σC groups showed no clinical signs and body weights comparable to the Mock group. The protection rate of the rHAdV5-ARV-σC + ARV-SDAU-1 group was 86% (26/30). The C group showed significantly reduced spleen, bursa, and thymus indices compared to the ARV-SDAU-1, rHAdV5-ARV-σC+ARV-SDAU-1, and Mock groups (P < 0.01) (Fig. 3C), indicating ARV-induced immune organ damage. No significant differences in immune organ indices were observed between the rHAdV5-ARV-σC, rHAdV5-ARV-σC+ARV-SDAU-1, and Mock groups (P > 0.05). Protective efficacy and clinical assessment of the rHAdV5-ARV-σC. Schematic of the immunization and challenge protocol. One-day-old chicks were immunized intramuscularly with a 100 µL dose of the vaccine of rHAdV5-ARV-σC (109 PFU). At 7 days old, the chicks were challenged with 100 ELD₅₀ SDAU-1 (oral). Samples were collected at 7, 14,21 and 28 dpc. Changes in body weight for each group over time. (C) Immune organ indices (spleen, thymus and bursa of Fabricius) at 7, 14 and 21 dpc. All data are presented as the mean±standard deviation (SD). Statistical significance is indicated as follows: ns, not significant, p > 0.05; *p < 0.05; **p < 0.01; ***p < 0.001. Viral shedding in cloacal swabs was significantly lower in the rHAdV5-ARV-σC+ARV-SDAU-1 group than in the C group at all time points (P < 0.01). At 15 dpc, only 13.3% (2/15) of rHAdV5-ARV-σC+ARV-SDAU-1 samples were positive for ARV RNA, compared to 80% (12/15) of ARV-SDAU-1 samples (Table 1). Tissue viral loads (liver, spleen, bursa of Fabricius, thymus, duodenum) in the rHAdV5-ARV-σC+ARV-SDAU-1 group were significant lower than those in the ARV-SDAU-1 group at 3, 7, 14 and 21 dpc (P < 0.01) (Table 2). Viral loads in the ARV-SDAU-1 group remained high until 21 dpc, while those in the rHAdV5-ARV-σC+ARV-SDAU-1 group declined rapidly after 7 dpc. Because viral shedding had dropped significantly by 15 dpc and tissue viral loads remained at very low levels up to 21 dpc, further testing at 21 and 28 dpc was not performed to minimize animal stress and unnecessary sacrifices. Table 1Viral shedding in cloacal swabs of chickens after ARV challenge (positive rate, %).Table 1 dummy alt textGroup3 dpc7 dpc11 dpc15 dpcrHAdV5-ARV-σC + ARV-SDAU-140.0a26.7a20.0a13.3aARV-SDAU-186.7b93.3b86.7b80.0brHAdV5-ARV-σC0.00.00.00.0Mock0.00.00.00.0a, b Values within the same column with different superscripts are significantly different (P < 0.01). dpc = days post-challenge. Viral shedding in cloacal swabs of chickens after ARV challenge (positive rate, %). a, b Values within the same column with different superscripts are significantly different (P < 0.01). dpc = days post-challenge. Table 2Viral load in tissues of chickens after ARV challenge (log₁₀ copies/μg RNA, mean ± SD).Table 2 dummy alt textTissueGroup3 dpc7 dpc14 dpc21 dpcLiverrHAdV5-ARV-σC + ARV-SDAU-13.21 ± 0.45a2.87 ± 0.38a1.98 ± 0.25a1.23 ± 0.18aARV-SDAU-16.78 ± 0.62b7.12 ± 0.59b6.54 ± 0.47b5.89 ± 0.39bSpleenrHAdV5-ARV-σC + ARV-SDAU-13.56 ± 0.41a3.12 ± 0.35a2.21 ± 0.28a1.45 ± 0.21aARV-SDAU-17.01 ± 0.58b7.34 ± 0.61b6.89 ± 0.51b6.12 ± 0.43bBursa of FabriciusrHAdV5-ARV-σC + ARV-SDAU-13.89 ± 0.47a3.45 ± 0.39a2.56 ± 0.31a1.67 ± 0.24aARV-SDAU-17.45 ± 0.63b7.78 ± 0.65b7.23 ± 0.54b6.56 ± 0.46bThymusrHAdV5-ARV-σC + ARV-SDAU-13.34 ± 0.42a2.98 ± 0.36a2.12 ± 0.27a1.34 ± 0.19aARV-SDAU-16.89 ± 0.57b7.21 ± 0.60b6.67 ± 0.49b5.98 ± 0.41bDuodenumrHAdV5-ARV-σC + ARV-SDAU-13.67 ± 0.44a3.23 ± 0.37a2.34 ± 0.29a1.56 ± 0.22aARV-SDAU-17.12 ± 0.61b7.45 ± 0.63b6.98 ± 0.52b6.34 ± 0.44ba, b Values within the same row and time point with different superscripts are significantly different (P < 0.01). dpc = days post-challenge; rHAdV5-ARV-σC group and Mock group had undetectable viral loads. Viral load in tissues of chickens after ARV challenge (log₁₀ copies/μg RNA, mean ± SD). a, b Values within the same row and time point with different superscripts are significantly different (P < 0.01). dpc = days post-challenge; rHAdV5-ARV-σC group and Mock group had undetectable viral loads. Gross lesions in the ARV-SDAU-1 group included petechial hemorrhages in the duodenum, underdeveloped bursae, and hemorrhagic thymus. Only 13.3% (2/15) of rHAdV5-ARV-σC+ARV-SDAU-1 chicks showed mild duodenal hemorrhages, while the rHAdV5-ARV-σC and Mock groups had no gross lesions (Fig. 4). Histopathological analysis revealed severe lesions in the ARV-SDAU-1 group: ruptured tendon collagen fibers, lymphocyte depletion in the bursa and thymus, and blunted/ruptured duodenal villi. The rHAdV5-ARV-σC+ARV-SDAU-1 group showed only mild lymphocyte depletion and villous rupture in the 2 affected chicks, while the rHAdV5-ARV-σC and Mock groups were normal (Fig. 5). Gross pathological changes in SPF chicks at 35 dpc. Gross lesions in the C group included petechial hemorrhages in the duodenum, underdeveloped bursae and hemorrhagic thymus. Only 13.3% (2/15) of V+C chicks showed mild duodenal hemorrhages, while the V and Mock groups had no gross lesions. Histopathological analysis of tissues from SPF chicks at 35 dpc. The C group: ruptured tendon collagen fibers, lymphocyte depletion in the bursa and thymus and blunted/ruptured duodenal villi. The V+C group showed only mild lymphocyte depletion and villous rupture in the 2 affected chicks, while the V and Mock groups were normal. Discussion In the present study, a rHAdV5-vectored vaccine expressing the σC protein of a genotype I ARV field strain (rHAdV5-ARV-σC) was constructed and shown to be safe, immunogenic, and highly efficacious in SPF chickens. The vaccine induced a rapid and balanced immune response, provided 86% protection against early homologous challenge, and significantly mitigated viral replication, tissue damage, and immune organ damage. These findings highlight the potential of adenovirus-vectored subunit vaccines as a rapid-response platform for controlling antigenically variant ARV strains. The kinetics and magnitude of the antibody response elicited by rHAdV5-ARV-σC are remarkable. A peak IgG titer of 1:3500 was achieved as early as 7 days post-immunization, which compares favorably with results reported for bacterially or yeast-expressed σC subunit vaccines (Li, et al., 2026; Wu, et al., 2005). This accelerated response can be attributed to the intrinsic immunostimulatory properties of the adenovirus vector. Adenoviruses are known to activate innate immune pathways through Toll-like receptor 9 (TLR9) and the stimulator of interferon genes (STING) pathway, thereby creating a pro-inflammatory environment that potentiates the adaptive response (Tatsis and Ertl, 2004). The practical consequence was demonstrated in the challenge study: significant protection was achieved even though challenge was performed only six days after vaccination at one day of age. This early onset of immunity is highly desirable for broiler chickens, which have a short production cycle. In contrast, conventional inactivated vaccines generally require 2–3 weeks to establish protective immunity. The capacity of adenovirus-vectored vaccines to confer rapid protection in poultry has also been observed with H5N1 influenza, where a single in ovo or day-old vaccination provided early protective immunity (Gao, et al., 2006; Toro, et al., 2008). Furthermore, the significant elevation of both serum IFN-γ and IL-4 levels in our vaccinated chickens indicates a balanced Th1/Th2 response, which is critical for both viral clearance and long-lasting humoral protection. The σC protein has long been recognized as the primary target for type-specific neutralizing antibodies and a key determinant of ARV pathogenicity (Goldenberg, et al., 2010; Meanger, et al., 1995). Its role as an attachment protein and major capsid component is well established (Benavente and Martínez-Costas, 2007). The adenovirus-vectored expression of full-length σC used here builds upon earlier work with subunit approaches and extends the concept to a viral-vectored platform that offers distinct advantages (Goldenberg, et al., 2016; Li, et al., 2026). First, the recombinant virus exhibited genetic stability over 13 passages, indicating that the expression cassette is stably maintained—a property important for large-scale manufacturing (Vemula and Mittal, 2010). Second, the vector backbone itself contributes to immunogenicity, potentially reducing or even eliminating the need for adjuvants. Third, adenovirus vectors allow the insertion of additional antigen genes, enabling the development of multivalent vaccines targeting multiple circulating genotypes or even different avian pathogens. A major obstacle in ARV control is the antigenic mismatch between traditional vaccine strains (e.g., S1133) and the continuously emerging field variants. Molecular epidemiological studies have documented the extensive genetic diversity of ARV, with six genotypic clusters now recognized and many isolates showing low amino acid identity in the σC protein with vaccine strains (Lu, et al., 2015; Shabbir, et al., 2024; Tang and Lu, 2015). This divergence leads to escape from neutralizing antibodies induced by classical vaccines and underlies many vaccination failures (Lublin, et al., 2011). The plug-and-play nature of the rHAdV5-ARV-σC construct allows the σC gene to be rapidly exchanged to match the dominant circulating strain, thereby addressing antigenic drift in a timely manner. The high level of protection demonstrated here against the homologous SDAU-1 variant confirms that this strategy can be effectively employed to target contemporary genotype I variants that already differ from S1133. Protection against viral shedding is crucial for limiting flock transmission. In addition to maintaining body weight, vaccinated chickens exhibited markedly reduced cloacal shedding (only 13.3% positive at 15 dpc) and significantly lower viral loads in all tested tissues. This indicates that systemic immunization with rHAdV5-ARV-σC also impacts mucosal virus excretion, likely through the high levels of circulating antibodies and possibly through effector T cells. Moreover, the fact that immune organ indices (spleen, bursa, thymus) in vaccinated-challenged chickens remained comparable to those in mock controls demonstrates that the vaccine effectively prevented the severe ARV-induced immune organ damage that characterizes pathogenic infections.A limitation of this study is the lack of a formal, statistically analyzed scoring system for the histopathological lesions. Because such semi-quantitative scoring inherently carries a degree of observer subjectivity, we primarily relied on objective quantitative metrics, including qPCR viral loads and body weights, to evaluate vaccine efficacy, utilizing pathological observations as qualitative support. Additionally, formal gross lesion observations were conducted at the final experimental endpoint rather than during early necropsies. Typical macroscopic avian reovirus lesions take longer to fully manifest and are not prominently visible during the early acute phase of infection. Therefore, early tissue sampling was dedicated exclusively to viral load quantification and organ index determination, while late-stage observations were utilized to accurately assess protection against visible tissue damage. Several limitations should be considered for future development. The protective efficacy of rHAdV5-ARV-σC has so far only been demonstrated against a homologous genotype I challenge; cross-protection against genotypes II–VI remains to be evaluated and will likely require the inclusion of additional or consensus σC sequences. Another well-known challenge for viral-vectored vaccines in poultry is the interference from maternally derived antibodies (MDA), which can neutralize the vector prior to antigen expression (Meeusen, et al., 2007). The present study was conducted in SPF chickens without MDA; therefore, the performance of this vaccine in commercial broilers possessing ARV-specific MDA needs careful evaluation to determine the optimal vaccination schedule and dose. Finally, while the replication-defective HAdV5 vector is safe for the host, regulatory and public acceptance aspects regarding the use of a human adenovirus vector in food animals will need to be addressed, though previous and ongoing approvals of HAdV5-vectored veterinary vaccines have established a promising precedent (Gao, et al., 2006). In conclusion, rHAdV5-ARV-σC is a promising vaccine candidate that induces rapid, robust humoral and cellular immunity, provides early protection, and significantly reduces viral replication and immune organ damage. This adenovirus-vectored σC platform enables a rapid update strategy to match circulating field variants and therefore represents a powerful tool for the control of avian reovirus infections in the poultry industry. Funding declaration This study was supported by the Key R&D Program of Shandong Province (No. 2023CXGC010704), the Shandong Modern Agricultural Technology & Industry System (No. SDAIT11-04), and the TS Scholar Project (No. Tstp20240819). Ethics approval and consent to participate All animal experiments were conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals of the Institutional Animal Care and Use Committee (IACUC) of Shandong Agricultural University (Approval No.: SDAU-AEC-2023-0012). Animals were housed in SPF facilities with controlled temperature (25 ± 2°C), humidity (55 ± 5%), and a 12-h light/dark cycle, with ad libitum access to feed and water. Euthanasia was performed via intravenous injection of sodium pentobarbital (50 mg/kg body weight) to minimize animal suffering, adhering to the 3R principles (Replacement, Reduction, Refinement). Author Contributions Xiyao Cui: Performed the recombinant human adenovirus type 5 vaccine construction, conducted the main animal experiments, analyzed the experimental data, and drafted the manuscript. Zhenrui Song: Conceived the study, contributed to the experimental design, and assisted in interpreting the immunological and protective efficacy results. Defang Zhou, Liangyu Yang, Hongbo Chen, and Hui Zhang: Executed the specific pathogen free chicken immunization and challenge trials, collected biological samples, prepared and evaluated the histopathological sections, performed the neutralizing antibody evaluations, and participated in analyzing the protective efficacy data. Ziqiang Cheng: Conceived the research concept, supervised the entire study, guided the experimental design, interpreted the findings, and finalized the manuscript. Disclosures All of the authors declare that they have no conflicts of interest. References